DOENÇA DE TAY-SACHS - Genética - ufcspa

8)Champe PC, Harvey RA. Bioquímica Ilustrada, 2ª edição. Porto alegre Editora Artes
Médicas, 1996.
9) Hama Y, Li YT, Journal Biology and Chemical 272(5): 2828-33, 1997.Li SC:
Interaction of GM2 activator protein with glycosphingolipids.
10)Cotran RS, Kuman V, Robbins SL (eds). Patologia Estrutural e Funconal, 5ª edição.
Rio de Janeiro, Guanabara Koogan, 1996.
11)Hunda E, Graua A, Fogela W ett al: Progressive cerebellar ataxia, proximal
neurogenic weakness and ocular motor disturbances: hexosaminidase A deficiency with
late clinical onset in four siblings. Journal of the Neurological Sciences 145:25-31, 1997.
12) Devidayal, Marwaka RK, Singh P ett al: Ptosis in late infantile Tay-Sachs disease.
Indian Journal Pediatric 68(5): 463-5, 2001.
13) Navon R, Khosravi R, Melki J, ettal: Juvenile-onset spinal muscular atrophy caused
by compound heterozigosity for mutations in the HEXA gene. Ann Neurol 41(5):631-8,
1997.
14)Zelnik N, Khazanov V, Sheinkman A ett al: Clinical manifestations of psychiatric
patients who are carries of Tay-Sachs disease. Possible role of psychotropic drugs.
Neuropsychobiology 41(3): 127-31, 2000.
15) Thompson M: Genética Médica 5 ª edição, 1997.
16) www.uwcm.ao.uk
17) Myerowitz R, Costigan FC: The major defect in Ashkenazi Jews with Tay-Sachs
disease is an insertion in the gene for alpha-chain of beta-hexosaminidase. J Biol Chem
263(35):18587-9, 1988.
18) Navon R, Proia RL: The mutations in Ashkenazi Jews with adults GM2 gangliosidosis,
the adult form of Tay-Sachs disease. Science 243(4897):1471-4,1989.
49